Goldman drops Merck (MRK) to Neutral from Conviction Buy, citing a lack of near-term catalysts....

|About: Merck & Co Inc. (MRK)|By:, SA News Editor

Goldman drops Merck (MRK) to Neutral from Conviction Buy, citing a lack of near-term catalysts. "We expected earnings acceleration from greater-than-expected synergies and capital deployment to drive multiple expansion, but neither scenario has played out." Firm also expects Major Pharma to underperform the S&P, and drops the sector to Neutral from Attractive. MRK -2.3% premarket.